Morgan Stanley
MAZE

Morgan Stanley’s Maze Therapeutics MAZE Stock Holding History

Morgan Stanley’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03M Sell
135,168
-69,663
-34% -$1.83M ﹤0.01% 4373
2026
Q1 		$6.11M Sell
204,831
-53,255
-21% -$2.35M ﹤0.01% 3982
2025
Q4 		$10.7M Buy
258,086
+45,324
+21% +$1.56M ﹤0.01% 3550
2025
Q3 		$5.52M Buy
212,762
+180,981
+569% +$3.06M ﹤0.01% 4076
2025
Q2 		$390K Buy
31,781
+7,888
+33% +$82.1K ﹤0.01% 5576
2025
Q1 		$263K Buy
+23,893
New +$288K ﹤0.01% 5621

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Morgan Stanley's MAZE Position: Q2 2026 in Review

Morgan Stanley reduced its Maze Therapeutics (MAZE) stake by 34% in Q2 2026, selling an estimated $1.83M and leaving 135,168 shares worth $4.03M. The position accounts for ﹤0.01% of the portfolio, ranked #4373.

Morgan Stanley first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.7M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Morgan Stanley held 135,168 shares of Maze Therapeutics worth $4.03M as of Q2 2026.
  • Morgan Stanley sold 69,663 Maze Therapeutics shares in Q2 2026, an estimated $1.83M.
  • Maze Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4373 holding.
  • Morgan Stanley first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Morgan Stanley's Maze Therapeutics position peaked at $10.7M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.